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Identiﬁcation of pretransplantation risk factors is important in evaluating patient outcomes after hemato-
poietic stem cell transplantation. Current scoring schemes, such as the European Group for Blood and Marrow
Transplantation risk score or the Hematopoietic Cell Transplantation-Speciﬁc Comorbidity Index, may under-
rate disease and disease status at the time of transplantation. The recently published Disease Risk Index (DRI)
speciﬁcally investigates these aspects by deﬁning 4 risk groups (low, intermediate, high, very high) with
signiﬁcant differences in overall survival (OS). We retrospectively investigated whether the DRI could be
applied at the transplantation center of Geneva’s University Hospitals (Geneva, Switzerland), where 64% of
patients are underwent transplantation with T celledepleted grafts (TDEP). We analyzed 409 patients with
various hematological malignancies who underwent transplantation between January 1998 and October
2012. Using the DRI, the 4-year OS for the low, intermediate, high, and very high groups was 82%, 53%, 27%,
and 31%, respectively (P < .0001). For TDEP patients, the 4-year OS for low, intermediate, and high overall risk
groups was 86%, 53%, and 33%, respectively (P < .0001). As patients in the very high overall risk group are
usually not eligible for TDEP, our group comprised too few patients (n ¼ 3) for meaningful analysis. For non-
TDEP patients, the 4-year OS for low, intermediate, high, and very high overall risk groups was 63%, 54%, 22%,
and 18%, respectively (P < .0001). Our results conﬁrm the prognostic value of the DRI in a cohort with a
majority of TDEP patients.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT)
is a therapeutic option for many hematologic malignancies
[1,2], particularly for patients with high-risk disease. Unfor-
tunately, treatment is associated with a non-negligible
morbidity and mortality, mainly due to infections and graft-
versus-host disease (GVHD) [3]. The success of HSCT depends
on patient-related factors, such as age and comorbidities [4];
transplantation-related factors, such as donor type (matched
or mismatched, related or unrelated) and donor-recipient sex
combination; and the time interval from diagnosis to trans-
plantation [5]. Importantly, the type of disease and its status at
transplantation signiﬁcantly affect graft success [6-10].edgments on page 1328.
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14.04.023Identifying pretransplantation risk factors is important to
determine the risk of HSCT in terms of overall survival (OS),
progression-free survival (PFS), relapse incidence (RI), and
transplantation-related mortality (TRM). Current scoring
schemes that estimate the risk of HSCT and help trans-
plantation teams choose between different treatment mo-
dalities are The European Group for Blood and Marrow
Transplantation (EBMT) risk score [5] and the Hematopoietic
Cell TransplantationeSpeciﬁc Comorbidity Index (HCT-CI)
[4]. However, they do not allow a particular focus on disease
and disease status at the time of transplantation. Recently,
Armand et al. [11] proposed a Disease Risk Index (DRI), which
speciﬁcally investigates these characteristics. The DRI deﬁnes
3 risk groups for diseases (low, intermediate, high), and
disease status is classiﬁed into 2 risk groups (low, high) [11].
The 6 possible combinations yield 4 distinct groups with
different outcomes in term of OS, PFS, and RI. However, the
cohort studied by Armand et al. included very few patients
who underwent transplantation with T celledepleted grafts
(TDEP) and, to our knowledge, the DRI has not been tested inTransplantation.
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aims to determine whether the DRI is also valid for use at our
center where 64% of patients undergo transplantation with
TDEP.
METHODS
Patients
We analyzed a cohort of 409 consecutive patients who underwent their
ﬁrst HSCT at the stem cell transplantation center at Geneva’s University
Hospitals, Geneva, Switzerland, during a 14-year period (from January 1998
to October 2012). Patientswho underwent transplantation for nonmalignant
diseases and with syngeneic donors were excluded from the study. We
retrospectively collected pre-HSCT, HSCT, and post-HSCT data from our
transplantation database. Medical charts were reviewed for cytogenetic data
to stratify the risk for acute myeloid leukemia (AML) [12] and myelodys-
plastic syndrome (MDS) [13] in different risk groups. Fifteen patients (11%)
with AML and 13 (20%) with MDS, for whom cytogenetic data were missing,
were classiﬁed as intermediate risk. Five patients with biphenotypic acute
leukemia (4with normal cytogenetics,1withmissing data)were classiﬁed in
the same disease group as AML intermediate risk.
All 409 patients were stratiﬁed into the 3 risk groups for disease (low,
intermediate, high) and 2 risk groups for disease status (low, high) to
determine their DRI [11].
Transplantation
Patients underwent transplantation with different conditioning regi-
mens. Myeloablative conditioning usually consisted of cyclophosphamide
(120 mg/kg) with either total body irradiation (10 to 12 Gy) or busulfan
(16mg/kg oral or 12.8mg/kg intravenously) with (in the case of in vitroTcell
depletion) orwithoutmethylprednisolone (1000mg/m2). Reduced-intensity
conditioning (RIC) consisted mostly of ﬂudarabine (120 mg/m2) with
busulfan low dose (8mg/kg oral or 6.4mg/kg intravenously) with or without
antithymocyte globulin (7.5 mg/kg with Thymoglobulin [Genzyme Poly-
clonals S.A.S., Marcy, France] or 25 mg/kg with ATG-Fresenius [Fresenius
Medical Care, Oberdorf, Switzerland]) with (in the case of in vitro T cell
depletion) or without methylprednisolone (1000 mg/m2) (Table 1).
We used in vitro T cell depletion with alemtuzumab (Campath [Gen-
zyme Corporation, Cambridge, MA]) [14,15] mainly for patients in complete
remission at transplantation. TDEP were given on day þ0 followed by an
add-back of 100  106 donor T cells on day þ1. RIC patients without GVHD
received donor lymphocyte infusions (DLI) from day þ100 in incremental
doses starting with 5  105 CD3/kg for unrelated and 1  106/kg for related
donor transplantations. DLI could be used also in the case of mixed
chimerism or relapse.
Deﬁnitions
We deﬁned relapse as the recurrence of disease after complete remission
(CR) or partial remission (PR) and induction failure as persistent disease
without achieving remission of any type (CR or PR). PR was only used for
lymphoma. Chronic lymphocytic leukemia or multiple myelomas not in CR
after treatment at the time of transplantation were considered induction
failure. Myeloproliferative neoplasms previously treated with drugs without
intent to achieve CR, such as interferon, hydroxyurea, etc., were considered
as untreated. Matched related donors, matched unrelated donors, and mis-
matched donors were considered to be (mis)matched based on HLA typing
for HLA-A, -B, -C, -DRB1, and DQB1 alleles.
Outcomes
Primary outcomes were 4-year OS, PFS, RI, and TRM for each of the 4 DRI
groups, for all patients, TDEP, and non-TDEP patients. Secondary outcomes
were the effects of TDEP on acute and chronic GVHD.
Statistical Analysis
Baseline characteristics were reported descriptively and compared us-
ing the chi-square test or Fisher exact test. OS and PFS were calculated using
the Kaplan-Meier estimator [16], with surviving patients censored in
December 2012. Cumulative incidence estimates of GVHD, RI, and TRMwere
calculated with death from other causes deﬁned as competitive events.
Cox regression models of OS were constructed and included age, donor-
recipient sex combination, cytomegalovirus donor-recipient status, donor
type, DRI, TDEP, source of stem cells, and conditioning regimen as covariates
for their association with OS. All calculations were done using SPSS version
21.0 (IBM Corp. Armonk, NY) and R version 3.0.1 (the Comprehensive R
Archive Network [CRAN] project [http://cran.us.r-project.org]).RESULTS
Patients
Baseline characteristics of the 409 patients in our cohort
are shown in Table 1.
Classiﬁcation of patients based on disease and disease
status risk according to the DRI proposed by Armand et al.
[11] resulted in low, intermediate, high, and very high DRI
groups comprising 45, 240, 110, and 14 patients, of whom 37,
177, 44, and 3 had received a TDEP and 8, 63, 66 and 11 had
not received TDEP.
Outcomes and DRI Relevance
The 4-year OS and PFS for all patients were 49% (95%
conﬁdence interval [CI], 44% to 54%) and 41% (95% CI, 35% to
46%), respectively. The 4-year RI was 38% (95% CI, 33% to 43%)
and TRM was 21% (95% CI, 17% to 25%). Using the DRI, the 4-
year OS for low, intermediate, high, and very high groups was
82% (95% CI, 70% to 93%), 53% (95% CI, 46% to 60%), 27% (95%
CI, 17% to 37%), and 31% (95% CI, 2% to 59%), respectively; P <
.0001 (Figure 1A). Four-year PFS for low, intermediate, high,
and very high DRI groups was 75% (95% CI, 61% to 88%), 43%
(95% CI, 36% to 50%), 22% (95% CI, 13% to 31%), and 20% (95%,
CI 0 to 43%), respectively (P< .0001) (Figure 2A). As expected,
the patient’s DRI score predicted the OS and PFS. Four-year RI
for low, intermediate, high, and very high DRI groups was 9%
(95% CI, 3% to 20%), 36% (95% CI, 30% to 43%), 50% (95% CI, 37%
to 60%), and 61% (95% CI, 28% to 82%), respectively; P < .0001
(Figure 3A). By contrast, 4-year TRMwas similar for low (18%;
95% CI, 8% to 30%), intermediate (19%; 95% CI, 14% to 25%),
high (27%; 95% CI, 18% to 36%), and very high (18%; 95% CI,
19% to 48%) DRI groups; P ¼ .59 (Figure 3A).
Outcomes by DRI and TDEP
We analyzed also OS, PFS, RI, and TRM for TDEP patients.
Four-year OS for low, intermediate, and high DRI groups
(n ¼ 258; the 3 patients with a very high DRI were not
included in the analysis) was 86% (95% CI, 74% to 98%), 53%
(95% CI, 45% to 60%), and 33% (95% CI, 18% to 48%), respec-
tively; P < .0001 (Figure 1B). Four-year PFS for low, inter-
mediate, and high DRI groups was 81% (95% CI, 67% to 94%),
41% (95% CI, 34% to 49%), and 26% (95% CI, 12% to 39%),
respectively; P < .0001 (Figure 2B). Four-year RI for low, in-
termediate, and high DRI groups was 11% (95% CI, 3% to 25%),
38% (95% CI, 31% to 46%), and 57% (95% CI, 41% to 71%),
respectively; P < .0001 (Figure 3B). We found no signiﬁcant
differences in the 4-year TRM among low, intermediate, and
high DRI groups; 14% (95% CI, 4% to 30%), 20% (95% CI, 15% to
27%), and 17% (95% CI, 7% to 30%), respectively; P ¼ .34
(Figure 3B).
Outcomes by DRI and non-TDEP
OS, PFS, RI, and TRM was analyzed for non-TDEP patients.
Four-year OS for low, intermediate, high, and very high DRI
groups was 63% (95% CI, 28% to 97%), 54% (95% CI, 40% to
67%), 23% (95% CI, 8% to 35%), and 18% (95% CI, 0 to 47%),
respectively; P ¼ .0003 (Figure 1C). Four-year PFS for low,
intermediate, high, and very high DRI groups was 47% (95%
CI, 10% to 84%), 49% (95% CI, 35% to 63%), 20% (95% CI, 7% to
32%), and 15 (95% CI, 0 to 42%), respectively; P ¼ .0002
(Figure 2C). Four-year RI for low, intermediate, high and very
high DRI groups was 14% (95% CI, 4% to 50%), 31% (95% CI, 19%
to 44%), 47% (95% CI, 31% to 61%), and 61% (95% CI, 28% to
82%) respectively; P ¼ .001 (Figure 3C). Regarding the entire
Table 1
Patient Characteristics
Characteristic TDEP % Non TDEP % Total % P Value
No. patients 261 63.8 148 36.2 409
Age, median (range), yr 43 (2-70) 43 (3-70) 43 (2-70)
Gender
Male 149 57.1 92 62.2 241 58.9 .31
Female 112 42.9 56 37.8 168 41.1
Disease
CML 33 12.6 9 6.1 42 10.3 <.05
CLL 9 3.4 3 2.0 12 2.9 .41
AML 95 36.4 46 31.1 141 34.5 .28
Favorable cytogenetic* 0 .0 0 .0 0 .0
Intermediate cytogenetic*,y,z 83 31.8 35 23.6 118 28.9
Adverse cytogenetic* 12 4.6 11 7.4 23 5.6
MDS 40 15.3 25 16.9 65 15.9 .68
Intermediate cytogeneticx,k 34 13.0 18 12.2 52 12.7
Adverse cytogeneticx 6 2.3 7 4.7 13 3.2
ALL 39 14.9 20 13.5 59 14.4 .69
Myeloproliferative neoplasms 9 3.4 5 3.4 14 3.4 .97
Multiple myeloma 12 4.6 15 10.1 27 6.6 <.05
Hodgkin lymphoma 6 2.3 8 5.4 14 3.4 .10
Non-Hodgkin lymphoma 19 7.3 16 10.8 35 8.6 .22
Indolent B-NHL 5 1.9 2 1.4 7 1.7
Aggressive B-NHL 5 1.9 5 3.4 10 2.4
Mantle cell lymphoma 5 1.9 6 4.1 11 2.7
T cell lymphoma, nodal 2 .8 2 1.4 4 1.0
T cell lymphoma, extranodal 2 .8 1 .7 3 .7
Stage at transplantation
CR 1 109 41.8 34 23.0 143 35.0 <.05
CR >1 46 17.6 24 16.2 70 17.1 .72
Untreated 28 10.7 5 3.4 33 8.1 <.05
Induction failure 24 9.2 47 31.8 71 17.4 <.05
Active relapse 15 5.7 26 17.6 41 10.0 <.05
PR 1 1 .4 0 .0 1 .2 .64
PR >1 (RIC) 5 1.9 3 2.0 8 2.0 .94
CP 31 11.9 8 5.4 39 9.5 <.05
AP or BC 2 .8 1 .7 3 .7 .70
Disease risk
Low 47 18.0 14 9.5 61 14.9 <.05
Intermediate 195 74.7 114 77.0 309 75.6 .60
High 19 7.3 20 13.5 39 9.5 <.05
Stage risk
Low 220 84.3 74 50.0 294 71.9 <.05
High 41 15.7 74 50.0 115 28.1 <.05
DRI
Low 37 14.2 8 5.4 45 11.0 <.05
Intermediate 177 67.8 63 42.6 240 58.7 <.05
High 44 16.9 66 44.6 110 26.9 <.05
Very high 3 1.1 11 7.4 14 3.4 <.05
Donor match
Identical sibling donor 129 49.4 73 49.3 202 49.4 .98
Matched unrelated donor 79 30.3 61 41.2 140 34.2 <.05
Mismatched unrelated donor 37 14.2 13 8.8 50 12.2 .11
Mismatched relative 16 6.1 0 .0 16 3.9 <.05
Matched other relative 0 .0 1 .7 1 .2 .36
Graft source
PBSC 242 92.7 113 76.4 355 86.8 <.05
BM 18 6.9 28 18.9 46 11.2 <.05
CB 0 .0 7 4.7 7 1.7 <.05
PBSCþBM 1 .4 0 .0 1 .2 .64
Conditioning
MAC 192 73.6 74 50.0 266 65.0 <.05
RIC 69 26.4 74 50.0 143 35.0
DLI given
No 144 55.2 125 84.5 269 65.8 <.05
Yes 117 44.8 23 15.5 140 34.2
GVHD prophylaxis
Cyclosporine 260 99.6 145 98.0 405 99.0 .14
Tacrolimus 0 .0 2 1.4 2 .5 .13
MTX 115 44.1 71 48.0 186 45.5 .45
MMF 57 21.8 66 44.6 123 30.1 <.05
CST 1 .4 2 1.4 3 .7 .30
CML indicates chronic myelogenous leukemia; CLL, chronic lymphocytic leukemia; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; CP,
chronic phase; AP, accelerated phase; BC, blast crisis; PBSC, peripheral blood stem cell; BM, bonemarrow; CB, cord blood; MAC, myeloablative conditioning; DLI,
donor lymphocytes infusion; GVHD, graft-versus-host disease; MTX, methotrexate; MMF, mycophenolate mofetil; CST, corticosteroids.
* Classiﬁed according to Armand et al. [12].
y Included 5 patients with biphenotypic leukemia.
z Included 15 patients with missing cytogenetic data.
x Classiﬁed according to Armand et al. [13].
k Included 13 patients with missing cytogenetic data.
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Figure 1. Overall survival stratiﬁed by Disease Risk Index group. (A) All
patients. (B) T celledepleted patients. (C) NoneT celledepleted patients.
Figure 2. Progression-free survival stratiﬁed by Disease Risk Index group. (A)
All patients. (B) T celledepleted patients. (C) NoneT celledepleted patients.
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Figure 3. Transplantation-related mortality and relapse incidence stratiﬁed by
Disease Risk Index group. (A) All patients. (B) T celledepleted patients. (C)
NoneT celledepleted patients.
Table 2
Patient Outcomes
A. All Patients
OR n OS (95% CI)
(P < .0001)
PFS (95% CI)
(P < .0001)
RI (95% CI)
(P < .0001)
TRM (95% CI)
(P ¼ .59)
L 45 82 (70-93) 71 (58-85) 9 (3-20) 18 (8-30)
I 240 53 (46-60) 43 (36-50) 36 (30-43) 19 (14-25)
H 110 27 (17-37) 22 (13-32) 50 (37-60) 27 (18-36)
VH 14 31 (2-59) 20 (0-43) 61 (28-82) 18 (19-48)
B. TDEP Patients
OR n OS (95% CI)
(P < .0001)
PFS (95% CI)
(P < .0001)
RI (95% CI)
(P < .0001)
TRM (95% CI)
(P ¼ .34)
L 37 86 (74-98) 81 (67-94) 11 (3-25) 14 (4-30)
I 177 53 (45-60) 41 (34-49) 38 (31-46) 20 (15-27)
H 44 33 (18-48) 26 (12-39) 57 (41-71) 17 (7-30)
VH 3 NA NA NA NA
C. Non-TDEP Patients
OR n OS (95% CI)
(P < .0003)
PFS (95% CI)
(P < .0002)
RI (95% CI)
(P < .0001)
TRM (95% CI)
(P ¼ .85)
L 8 63 (28-97) 47 (10-84) 14 (4-50) 44 (12-73)
I 63 54 (40-67) 49 (35-63) 31 (19-44) 17 (9-28)
H 66 22 (8-35) 20 (7-32) 47 (31-61) 32 (20-44)
VH 11 18 (0-47) 15 (0-42) 69 (26-90) 10 (3-41)
OR indicates overall risk; L, low; I, intermediate; H, high; VH, very high;
NA, not available.
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TRM among low, intermediate, high DRI, and very high DRI
groups (44% [95% CI, 12% to 73%]; 17% [95% CI, 9% to 28%], 32%
[95% CI, 20% to 44%], and 10% [95% CI, 3% to 41%], respec-
tively; P ¼ .085) (Figure 3C).
All results are summarized in Table 2. The impact of the
DRI on OS was conﬁrmed by multivariate analysis (Table 3).
Infusion of DLI
One hundred forty patients (117 TDEP patients) received a
DLI. Seventy-six DLI were given for relapse (2 for increased
paraprotein, 3 for decreasing donor chimerism, 17 for mo-
lecular relapse, and 54 for hematological relapse). In addi-
tion, 64 TDEP patients received DLI as dictated by our
transplantation protocol. Patients received a median of 2
(range, 1 to 7) DLI with a median dose of 1.6  106 CD3/kg
(range, .1 to 257  106/kg).
Comparison of DRI Outcomes with the Study by
Armand et al.
Table 4 shows that the OS and PFS in the low-risk group
were somewhat higher than those reported by Armand et al.
[11], although the impact of being ranked in a particular DRI
group was similar. This was true for the entire cohort,
including TDEP patients.
DISCUSSION
Risk stratiﬁcation to predict HSCT patient outcomes is
essential and several scoring schemes have already been
tested, such as the EBMT score [5] or the HCT-CI [4]. Armand
et al. [11] have proposed a new tool, the DRI, which gives
prominence to disease and disease status at time of trans-
plantation, including the high impact cytogenetic classiﬁca-
tions for AML and MDS [17]. However, to the best of our
knowledge, the DRI has not been tested yet for TDEP HSCT
patients. In this retrospective study, we conﬁrm the feasi-
bility and validity of the DRI score in the speciﬁc setting of
TDEP HSCT. The 4-year OS, PFS, and RI were statistically
Table 3
Multivariate Analysis for Overall Survival
Variable HR Lower
95% CI
Higher
95% CI
P Value
Age, yr
<20 Ref
20-40 1.435 .819 2.514 .207
>40 1.667 .969 2.866 .065
Donor-recipient sex combination
Others Ref
Female donor-male recipient 1.030 .733 1.448 .866
CMV donor-recipient combination
Donor negative-recipient negative Ref .
Donor positive-recipient negative 1.049 .655 1.681 .842
Donor negative-recipient positive 1.491 1.006 2.209 .047
Donor positive-recipient positive 1.066 .734 1.549 .735
Donor type
MRD Ref
MUD 1.658 1.188 2.315 .003
MMD 2.989 1.985 4.505 .000
DRI
Low Ref
Intermediate 3.352 1.611 6.976 .001
High 5.434 2.536 11.643 .000
Very high 7.883 2.835 21.896 .000
T celledepleted graft
No TDEP Ref
TDEP .744 .528 1.048 .090
Stem cell source
PBSC Ref
BM 1.597 1.021 2.496 .040
CB .781 .222 2.742 .700
Conditioning regimen
MAC Ref
RIC .934 .676 1.294 .686
HR indicates hazard ratio; Ref, reference group; CMV, cytomegalovirus;
MRD, matched related donor; MUD, matched unrelated donor; MMD,
mismatched donor.
Table 4
Comparison of Disease Risk Index Outcomes with Study Results of Armand et al.
Overall Survival (95% CI)
OR Study Cohort All
Patients (P < .0001)
Study Cohort T Celledepleted
Patients (P < .0001)
L 82% (70%-93%) 86% (74%-98%)
I 53% (46%-60%) 53% (45%-60%)
H 27% (17%-37%) 33% (18%-48%)
VH 31% (2%-59%) NA
Progression-free Survival (95% CI)
OR Study Cohort All
patients (P < .0001)
Study Cohort T Celledepleted
Patients (P < .0001)
L 75% (61%-88%) 81% (67%-94%)
I 43% (36%-50%) 41% (34%-49%)
H 22% (13%-31%) 26% (12%-39%)
VH 20% (0-43%) NA
Relapse Incidence (95% CI)
OR Study Cohort All
Patients (P < .0001)
Study Cohort T Celledepleted
Patients (P < .0001)
L 9% (3%-20%) 11% (3%-25%)
I 36% (30%-43%) 38% (31%-46%)
H 50% (37%-60%) 57% (41%-71%)
VH 61% (28%-82%) NA
Transplantation-related Mortality (95% CI)
OR Study Cohort All
Patients (P ¼ .59)
Study Cohort T Celledepleted
Patients (P ¼ .34)
L 18% (8%-30%) 14% (4%-30%)
I 19% (14%-25%) 20% (15%-27%)
H 27% (18%-36%) 17% (7%-30%)
VH 18% (19%-48%) NA
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statistical signiﬁcance.
In our transplantation center, we use TDEP mostly in
patients in CR or in the chronic phase of chronic myeloid
leukemia to avoid severe acute and chronic GVHD [18,19]
that would increase the risk of infection [20], impair func-
tional status, and decrease the patient’s quality of life [21,22].
In most of these patients, we infused a TDEP followed by a
dose of 100  106 T cells/kg the day after. Depending on the
conditioning regimen, escalated doses of DLI were given after
tapering immunosuppression (usually starting on day þ100
for RIC). DLI was not given automatically for myeloablative
conditioning.
Four-year OS, PFS, RI, and TRM for TDEP were not statis-
tically signiﬁcant different from the results in our entire
cohort. The DRI correlated well with OS, PFS, and RI in TDEP
patients, but not with TRM. The latter is not surprising
because disease and disease status at the time of trans-
plantation and the related risk of relapse should be at least as
important in TDEP patients as in non-TDEP patients, whereas
the opposite is true for TRM.
We consider that the strength of the new scoring tool is
the stronger emphasis on disease and disease status to pre-
dict HSCT outcomes. Moreover, it is easy to apply because of
the low number of disease risk groups (only 3), disease status
groups (only 2), and the relatively simple cytogenetic clas-
siﬁcations of AML [12] and MDS [13]. The DRI score could be
used to assess the determinants associated with the risk of
HSCT together with other tools, such as the EBMT or HCT-CI
risk scores. However, its simplicity may also render the score
less precise, as molecular markers of disease status, recently
described as independent prognostic factors, are not in-
cluded [23-26]. For instance, mutations of NPM1 [23] or
CEBPA [23] in AML are of good prognosis, whereas mutationsStudy Cohort NoneT Celledepleted
Patients (P ¼ .003)
Armand et al. (P < .001)
63% (28%-97%) 64% (56%-70%)
54% (40%-67%) 46% (42%-50%)
22% (8%-35%) 26% (21%-31%)
18% (0-47%) 6% (0-21%)
Study Cohort NoneT Celledepleted
Patients (P ¼ .003)
Armand et al. (P < .001)
47% (10%-83%) 56% (48%-63%)
49% (35%-63%) 40% (36%-43%)
20% (7%-32%) 18% (14%-22%)
15% (0-42%) 6% (0-21%)
Study Cohort NoneT Celledepleted
Patients (P ¼ .001)
Armand et al. (P < .001)
14% (4%-50%) 19% (13%-24%)
31% (19%-44%) 36% (33%-40%)
47% (31%-61%) 55% (50%-60%)
69% (26%-90%) 63% (44%-81%)
Study Cohort NoneT Celledepleted
Patients (P ¼ .85)
Armand et al. (P ¼ .11)
44% (12%-73%) 26% (19%-32%)
17% (9%-28%) 24% (21%-27%)
32% (20%-44%) 27% (22%-32%)
10% (3%-41%) 31% (18%-45%)
Y. Beauverd et al. / Biol Blood Marrow Transplant 20 (2014) 1322e13281328of FLT3-ITD [24,25] and hyperexpression of EVI1 [26] are of
poor prognosis. Thus, the DRI may have to be adapted by
adding molecular markers to the current cytogenetic ones.
Similarly, additional cytogenetic markers could be added for
patients with myeloma where t(4;14) and del(17p) are
associated with a worse prognosis [27].
The present study has some limitations. It was retro-
spective and covered a long period (14 years), during which
supportive care and the efﬁcacy of antifungal prophylaxis
have evolved and improved over time. Despite these limi-
tations, however, the data reported herein are informative.
Our data conﬁrm that patients undergoing HSCT can be
stratiﬁed into 4 DRI groups with statistically signiﬁcant
different outcomes. In addition, this new scoring scheme can
be applied also to TDEP HSCT patients with a lower incidence
of acute GVHD and could serve as an additional tool to help
physicians determine individual risks and beneﬁts of HSCT.
In conclusion, our data illustrate the prognostic value of
the DRI in a cohort with a majority of TDEP patients.
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